Cell Medica is developing transformative new treatments for cancer based genetically engineering the patient’s immune cells to recognize and kill and malignant cells. Our strategy targets solid tumors and includes both autologous and allogeneic (off-the-shelf) cell therapies incorporating chimeric antigen receptors (CARs) and engineered T cell receptors (TCRs). Other technologies in our portfolio include EBV-specific T cells for the treatment of lymphomas associated with the Epstein Barr virus.